ABBV · News · 20260915N

Acquisition / Partnership / Divestiture

AbbVie Inc. · 2026-09-15 · Importance 31 · Surprise 42 · In source text

MarketBeat reported that AbbVie is using the Apogee deal to support growth after HUMIRA, with a strategy focused on immunology, neuroscience, oncology and obesity. Executives highlighted plans to expand beyond the established SKYRIZI and RINVOQ franchises. The digest did not disclose the Apogee transaction value, expected closing date, or quantified financial impact.

Key facts

• AbbVie has a deal with Apogee (referred to as the "Apogee Deal"). source
• AbbVie and BioLabs University of Toronto have announced the opening of applications for the AbbVie Biotech Innovators Award. source
• AbbVie has partnered with the PGA TOUR to become its official pharmaceutical sponsor and the sponsor of the 2026 Presidents Cup. source
• The Birdies for Brain Health campaign will scale in 2027 to include donations for every birdie made at PGA TOUR Signature Events and FedExCup Playoffs. source
• AbbVie executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity. source
• AbbVie highlighted plans to expand beyond the company's established SKYRIZI and RINVOQ franchises. source
• Two winning companies of the AbbVie Biotech Innovators Award will receive a year of free laboratory space, equipment access, and mentorship from AbbVie's experts. source
• The partnership introduces "Birdies for Brain Health," a multi-year campaign with initial donations going to six patient advocacy organizations. source

Impact estimates